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ABSTRACT
Introduction: Invasive aspergillosis (IA) is
associated with a significant clinical and
economic burden. The phase III SECURE trial
demonstrated non-inferiority in clinical efficacy
between isavuconazole and voriconazole. No
studies have evaluated the cost-effectiveness of
isavuconazole compared to voriconazole. The
objective of this study was to evaluate the costs
and cost-effectiveness of isavuconazole vs.
voriconazole for the first-line treatment of IA
from the US hospital perspective.
Methods: An economic model was developed
to assess the costs and cost-effectiveness of
isavuconazole vs. voriconazole in hospitalized
patients with IA. The time horizon was the
duration of hospitalization. Length of stay for
the initial admission, incidence of readmission,
clinical response, overall survival rates, and
experience of adverse events (AEs) came from
the SECURE trial. Unit costs were from the
literature. Total costs per patient were
estimated, composed of drug costs, costs of
AEs, and costs of hospitalizations. Incremental
costs per death avoided and per additional
clinical responders were reported.
Deterministic and probabilistic sensitivity
analyses (DSA and PSA) were conducted.
Results: Base case analysis showed that
isavuconazole was associated with a $7418
lower total cost per patient than voriconazole.
In both incremental costs per death avoided
and incremental costs per additional clinical
responder, isavuconazole dominated
voriconazole. Results were robust in sensitivity
analysis. Isavuconazole was cost saving and
dominant vs. voriconazole in most DSA. In
PSA, isavuconazole was cost saving in 80.2% of
the simulations and cost-effective in 82.0% of
the simulations at the $50,000 willingness to
pay threshold per additional outcome.
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Conclusion: Isavuconazole is a cost-effective
option for the treatment of IA among
hospitalized patients.
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INTRODUCTION
Invasive aspergillosis (IA) is a fungal infection
that primarily affects immunocompromised
individuals. In 2013, a total of 2990
hospitalizations with a primary diagnosis of
IA, and 14,470 hospitalizations with either a
primary or secondary diagnosis of IA, occurred
in the USA [1]. Risk factors for IA include the
presence of hematological malignancies,
hematopoietic stem cell or solid organ
transplant, severe and/or prolonged
neutropenia, prolonged and/or high-dose
immunosuppressive therapy, and
chemotherapy [2]. The majority of cases of IA
are encountered in patients with hematological
malignancies and bone marrow transplant
patients (43.0–68.0%), with the remainder of
cases occurring in solid organ transplant
recipients (13.0–17.0%) and other
immunocompromised hosts (10.0–15.0%)
[3, 4].
IA is a serious, life-threatening condition.
The reported 1-year overall survival rate
following a diagnosis of IA among bone
marrow transplant patients ranges from 10.0
to 40.0% in the literature [5, 6]. Among
critically ill patients admitted to an intensive
care unit with proven IA, overall survival rates
at 84 days after diagnosis of IA have been
reported to be 21.0% [7]. A 2010 analysis of a
national hospital administrative database found
that the median length of hospitalization
among patients diagnosed with IA was
18–26 days (depending on whether IA was a
primary or secondary diagnosis) [8]. During this
time, hospitals incurred a median cost between
$32,465 and $68,008 (2006 USD), with
antifungal medications accounting for
6.0–10.2% of those costs [8]. A 2009 analysis
of data from the 2003 Nationwide Inpatient
Sample concluded that the length of
hospitalization for immunocompromised
patients with IA was 1.8–12.4 times higher
than the length of hospitalization of similarly
high-risk immunocompromised patients
without IA and the median hospital charges
were 2.3–12.7 times higher (depending on
diagnosis-related group) [9]. The annual total
cost of IA in the USA, including
hospitalizations, subsequent home healthcare,
and outpatient medications, was estimated to
be $674 million in 1998 [10], the equivalent of
$1.3 billion today.
Current treatment guidelines, published
before FDA approval of isavuconazonium
sulfate, recommend several antifungal agents
for the treatment of IA, including voriconazole,
amphotericin B and its lipid formulations,
itraconazole, posaconazole, and caspofungin
[11, 12]. Voriconazole, an antifungal triazole
that inhibits fungal respiration and cell
membrane function, is currently the preferred
agent for first-line treatment of IA, both from a
clinical [11] and an economic perspective
[13, 14]. Amphotericin B has a less favorable
safety profile [15] and lower efficacy [15]
compared to voriconazole, and it is
recommended for patients who cannot be
treated with voriconazole [11]. Other available
agents offer limited efficacy benefits compared
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to voriconazole and therefore are recommended
as salvage therapy agents after voriconazole or
amphotericin B treatment [11]. A literature
review conducted by Krueger and Nelson
identified 10 pharmacoeconomic analyses in
six different countries comparing voriconazole
to other options for the treatment of IA, and all
these analyses concluded that voriconazole was
the most cost-effective therapy compared to
other treatment options discussed above [13].
Another advantage of voriconazole is that it can
be administered both orally and intravenously
(IV). Voriconazole does present several possible
disadvantages: possible toxicity of the IV
formulation in patients with renal failure (due
to required co-administration with solubility
additive sulfobutylether-b-cyclodextrin)
[11, 14], a twice daily dosing schedule of the
oral medication because of relatively rapid
metabolization [14], and a known risk of
drug–drug interactions (due to its effect on the
CYP2C19, CYP2C9, and CYP3A4 metabolic
pathways) [11, 14].
Isavuconazonium sulfate, a novel triazole and
prodrug of isavuconazole, received FDA approval
for the treatment of IA and invasive
mucormycosis in March 2015 [16]. The approval
was granted on the basis of data from the SECURE
clinical trial (NCT00412893), which showed that
isavuconazole has comparable efficacy with
voriconazole [17]. All-cause mortality at day 42
(the SECURE trial primary endpoint) was similar
in both treatment groups (18.6% in the
isavuconazole-treated group and 20.2% in the
voriconazole-treated group). Overall adverse
event (AE) rates were also similar (96.1% of
isavuconazole-treated patients and 98.5% of
voriconazole-treated patients experienced at
least one treatment-emergent AE) [17]. However,
statistically significant differences were observed
in eye disorders, hepatobiliary disorders, and skin
disorders, with isavuconazole-treated patients
having significantly lower rates of these events
[17]. Similar to voriconazole, isavuconazole is also
available in both oral and IV formulations. Its IV
formulation, however, does not require solubility
additive sulfobutylether-b-cyclodextrin, which
has been associated with potential
nephrotoxicity in the voriconazole IV
formulation [18]. Oral isavuconazole has a
longer half-life than oral voriconazole, allowing
for once daily dosing. In addition, the
metabolism of isavuconazole is limited to the
CYP3A4 and CYP3A5 pathway [18].
In order to determine the optimal treatment
option, it is important to thoroughly evaluate
new therapies against existing standards by
comparing efficacy, safety, costs, and
cost-effectiveness. No existing study compares
the costs and cost-effectiveness of isavuconazole
vs. voriconazole. To fill this gap, the current
study has been conducted to estimate the total
cost per treated patient and evaluate the
cost-effectiveness of isavuconazole vs.




A cost-effectiveness decision tree model was
developed in Microsoft Excel 2010 (Fig. 1). The
target population included patients with
proven, probable, or possible invasive fungal
disease caused by the Aspergillus species or other
filamentous fungi (reflecting the SECURE trial
population) [17]. Two treatments,
isavuconazole and voriconazole, were
compared. The model estimated the total cost
per IA patient treated with each product, with
total cost defined as the sum of drug, AE, and
hospital stay costs. Incremental cost per death
avoided and the incremental cost per additional
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responder comparing isavuconazole to
voriconazole were also estimated. The model
was developed from a US hospital perspective,
in which only direct costs incurred during the
hospitalization were considered, with a time
horizon of one hospital stay (including
readmissions occurring within 30 days of the
original discharge). Readmission within 30 days
was considered given that it was a prespecified
endpoint in the clinical trial. Because this time
horizon is less than 1 year, discounting of costs
and effectiveness measures was not necessary.
This article does not contain any new studies
with human or animal subjects performed by
any of the authors. The model relied only on
the summary statistics from the SECURE trial
(ClinicalTrials.gov identifier NCT00412893)
and patient level data was not used.
Institutional review board (IRB) review was not
needed.
Efficacy and Safety Inputs
Efficacy inputs, mortality and clinical response,
for both treatment arms were extracted from
the SECURE trial (Table 1) [17]. Mortality was
the primary efficacy endpoint and clinical
response was the secondary endpoint in the
SECURE trial. As was previously described,
all-cause mortality at day 42 was 18.6% for
isavuconazole-treated patients and 20.2% for
voriconazole-treated patients [adjusted
difference = -1.0%, 95% CI (-7.8, 5.7%)] [17].
Clinical response rates were 62.0% and 60.3%,
respectively [adjusted difference = 0.4%, 95%
CI (-10.64, 11.53%)] [17]. The differences in
these two outcomes were not statistically
significant. The median length of stay of the
initial hospitalization was 13 days for
isavuconazole-treated patients and 15 days for
voriconazole-treated patients [19]. Following
Fig. 1 Clinical progression of patients through the model.
IA invasive aspergillosis. Hospitalized patients with IA
would enter the model and they could receive either
isavuconazole or voriconazole. While receiving treatments,
patients could experience adverse events related to
hepatobiliary, eye, and skin disorders. Patients were
evaluated for survival and clinical response at the end of
model cycle. Length of stay and likelihood of readmission
(not depicted here) are also considered in the calculation
of healthcare costs
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Table 1 Model inputs: efﬁcacy, dosing schedule, and costs
Deﬁnition Base case value Source/notes
Efﬁcacy ISAV VORI
Mortality rate 18.6% 20.2% SECURE trial [17]; measured at day 42 on the
basis of the intent to treat (ITT) population
Clinical response rate 62.0% 60.3% SECURE trial [17]; measured at end of
treatment on the basis of the modiﬁed ITT
population
Initial hospital length of stay, days 13.0 days 15.0 days SECURE trial [19]
30-day readmission rate 18.3% 24.4% SECURE trial [19]
Readmission length of stay, days 6.0 days Estimated from an administrative database study
of hospitalized patients with IA [20]
Dosing schedule Dose Frequency
(per day)
ISAV Product label [16, 22]
Day 1: IV infusion 372 mg 3
Day 2: IV infusion 372 mg 3
Day 3 to end of treatment
IV infusion 372 mg 1
Oral (tablet) 372 mg 1
VORI
Day 1: IV infusion 6 mg/kg 2
Day 2: IV infusion 4 mg/kg 2
Day 3 to end of treatment
IV infusion 4 mg/kg 2




ISAV 8.1 4.9 SECURE clinical trial data [17]
VORI 8.9 6.1
Drug cost (WAC) Cost per unit
ISAV ReadyPrice (Thomson) [23]
IV infusion (372 mg) $238.50
Oral (tablet) (186 mg) $70.00
VORI (generic)
IV infusion (200 mg) $122.07
Oral (tablet) (200 mg) $35.05
Hospitalization costa
Per diem cost of hospitalization
related to IA
$2898.31 HCUP NIS [1]
ISAV isavuconazole, VORI voriconazole, IV intravenous, HCUP NIS Healthcare Cost and Utilization Project National Inpatient
Sample
a Inﬂated to 2015 USD
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discharge from the initial hospitalization,
18.3% of isavuconazole-treated patients and
24.4% of voriconazole-treated patients had a
readmission within 30 days [adjusted
difference = -6.0%, 95% CI (-13.3, 1.3%)].
This difference was not statistically significant
[19]. The median length of stay for readmissions
(6 days) was obtained from an analysis of the
Premier database of inpatients with a diagnosis
of IA and who had a readmission [20]; in the
absence of other information, it was assumed to
be equal across treatment arms.
The model considered grade III and IV
AEs whose overall incidence significantly
differed between isavuconazole- and
voriconazole-treated patients in the SECURE
trial, i.e., eye disorders, hepatobiliary disorders,
and skin disorders (individually described in
ESM Appendix 1) [21].
Dosing Frequency and Duration Inputs
The dosing schedules for both voriconazole and
isavuconazole were based on the doses
administered in the SECURE trial [17], and
they are consistent with their respective
product labels [16, 22]. The current model
assumed there was no vial wastage. Both
isavuconazole and voriconazole were initiated
as an IV infusion and could subsequently be
converted to an oral formulation as early as
day 3, on the basis of physician evaluation. IV
voriconazole was dosed on the basis of patients’
weight, while administration of oral
voriconazole, IV and oral isavuconazole was
based on fixed dosing. The model assumed an
average patient weight of 75 kg to estimate costs
of IV voriconazole, which was the midpoint of
the average weight of 82 kg of adults older than
20 years of age in the USA and the mean weight
of 69 kg in the SECURE trial [21]. Details
regarding the dosing of each treatment arm
can be found in Table 1. The total duration of
isavuconazole treatment (including IV and oral
formulations) reported in the SECURE trial was
47.0 days on average, 8.1 days of which were IV
treatment [17]. Only drugs administered within
the hospital were considered; thus, the model
included the costs of 8.1 days of IV and 4.9 days
(13.0–8.1 days) of oral isavuconazole treatment.
The total duration of voriconazole treatment
was 46.4 days in the SECURE trial, 8.9 days of
which were IV treatment [17]. The model
considered voriconazole treatment as 8.9 days
of IV and 6.1 days (15.0–8.9 days) of oral dosing.
Cost Inputs
Prices of isavuconazole and voriconazole were
estimated on the basis of the wholesale
acquisition costs (WACs), obtained from
ReadyPrice (Thomson) (Table 1) [23]. Given
that generic voriconazole is already available
and with a lower price, the price of generic
voriconazole was used. The price of 200 mg of
voriconazole was $122.07 and $35.05 for the IV
and oral formulations, respectively. The price of
372 mg of isavuconazonium sulfate (equivalent
to 200 mg of isavuconazole) was $238.50 and
$70.00 for the IV and oral formulations,
respectively.
The per diem cost of hospitalization due to IA
was estimated at $2898.31, using the 2013 HCUP
Nationwide Inpatient Sample (NIS), a publicly
available database created and maintained by the
Agency for Healthcare Research and Quality
(AHRQ) [1]. The same per diem cost of
hospitalization was assumed for initial
hospitalizations and readmissions (Table 1). All
costs were inflated to 2015 USD [24].
The costs of managing AEs were estimated
using published literature [25–37]. For acute
AEs, the cost of managing the entire AE episode
was included and this cost was assumed to be
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equal among the treatment arms. For AEs which
could last beyond the initial hospitalization, the
cost per AE reported in literature (typically
reported as an annual cost) was prorated on
the basis of the length of initial hospital stay
(i.e., 13 days for isavuconazole and 15 days for
voriconazole) for each treatment arm. Prorating
AEs this way makes the assumption that those
AEs begin on the first day of IA therapy. This
assumption is used given the lack of detailed
information on time of AE onset and the fact
that costs of AE do not have a significant impact
on the model’s results. When no literature was
available, the cost of each AE was assumed to be
the cost of an inpatient consultation of
moderate complexity. In the case of
hepatobiliary disorders, the cost of a liver
function panel was also included.
Deterministic and Probabilistic Sensitivity
Analyses (DSA and PSA)
Deterministic sensitivity analysis (DSA) was
carried out by increasing and decreasing one
parameter at a time while maintaining the rest
of the inputs at the base case value. Treatment
duration, length of hospitalization (length of
stay), readmission rate, per diem cost of
hospitalization, drug costs, costs of AE
treatment, clinical response rates, and
mortality rates were all varied in the DSA to
evaluate their impact. In addition, a sensitivity
analysis assuming that a US payer perspective
was included. This payer perspective included
drug and AE costs throughout the total duration
of isavuconazole and voriconazole treatment.
The total duration was reported by Horn et al.
(including inpatient and outpatient) [19].
Another sensitivity analysis assumed equal
hospital length of stay, mortality, and clinical
response rate among isavuconazole- and
voriconazole-treated patients. For this analysis,
the average of each input for isavuconazole and
voriconazole was used for both treatments.
Sensitivity analyses were also conducted by
changing only the inputs of isavuconazole to
make it less favorable than voriconazole. The
parameter inputs were varied on the basis of
either the confidence interval, if available, or a
predefined percentage of the base case value
(ESM Appendix 2).
Probabilistic sensitivity analysis (PSA) was
carried out by assuming parametric
distributions for each input parameter and
resampling each parameter simultaneously
from their respective distributions to
re-estimate model outputs (ESM Appendix 2).
Treatment duration was assumed to follow
normal distributions, and mortality and clinical
response rates were assumed to follow beta
distributions. The standard errors of these
parameters were estimated from the SECURE
trial. The initial hospitalization length of stay
follows a uniform distribution, with the min and
max specified as ;25.0% of the base case value.
The per diem cost of hospitalization and the
costs of managing AEs were assumed to follow
gamma distributions, with standard errors
assumed to be equal to one quarter of their
respective means. Five-thousand random draws
were conducted. PSA was conducted for all three
outcomes: incremental cost per patient,
incremental cost per death avoided, and
incremental cost per clinical responder. For the
incremental cost per patient, the results of the
PSA were summarized in a cost-minimization
acceptability curve based on incremental cost
per patient. For the incremental cost per death
avoided and the incremental cost per clinical
responder, cost-effectiveness acceptability curves
were plotted on the basis of net monetary benefit
(NMB) values, which were estimated on the basis
of willingness to pay threshold9 incremental
benefit- incremental costs.
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RESULTS
The model estimated the total costs per treated
patient receiving isavuconazole and
voriconazole, the incremental cost per patient
treated with isavuconazole vs. voriconazole, the
incremental cost per death avoided
(isavuconazole vs. voriconazole), and the
incremental cost per clinical responder
(isavuconazole vs. voriconazole).
Isavuconazole was associated with a lower
total cost per patient compared to voriconazole
($44,748.38 vs. $52,166.16). This was a result of
lower drug costs ($3571.85 vs. $3869.99), lower
costs of AEs ($317.42 vs. $576.74), lower costs of
initial hospitalization ($37,678.04 vs.
$43,474.66), and lower costs of hospital
readmissions ($3181.07 vs. $4244.77) among
isavuconazole-treated patients than
voriconazole-treated patients. Isavuconazole
was dominant (lower costs and greater health
benefits) against voriconazole with respect to
incremental cost per death avoided and
incremental cost per clinical responder
(Table 2).
Isavuconazole was predicted to be associated
with lower total cost per patient than
voriconazole in each DSA except for when the
initial hospitalization length was increased by
25.0% for isavuconazole-treated patients and
left unchanged for voriconazole-treated
patients (Table 3). All other DSAs estimated a
lower cost for isavuconazole than voriconazole,
ranging from $1411.05 to $17,292.29 savings
per patient. The DSA using the US payer
perspective (including both inpatient and
outpatient drug and AE costs) estimated a cost
saving of $4849.26 for isavuconazole-treated
patients, compared to voriconazole-treated
patients. The DSA assuming equal LOS,
mortality, and clinical response for
isavuconazole and voriconazole estimated a
cost saving of $1411.05 for isavuconazole.
DSAs for incremental cost per death avoided
and incremental cost per clinical responder
showed isavuconazole was dominating against
voriconazole in all but two cases: when the
initial hospitalization length increased by
25.0% for isavuconazole-treated patients but
remained unchanged for voriconazole-treated
patients, and when the relevant efficacy
outcome, i.e., 42-day mortality rate or clinical
response rate, changed unfavorably for
isavuconazole but remained unchanged for
voriconazole (making isavuconazole worse
than voriconazole).
Table 2 Base case results: costs and cost-effectiveness of ISAV vs. VORI
Parameter ISAV VORI
Total cost per patient $44,748.38 $52,166.16
Total drug cost $3571.85 $3869.99
AE cost $317.42 $576.74
Initial hospitalization cost $37,678.04 $43,474.66
Hospital readmission cost $3181.07 $4244.77
Incremental cost per death avoided ISAV is dominant over VORIa
Incremental cost per additional clinical responder ISAV is dominant over VORIa
ISAV isavuconazole, VORI voriconazole, AE adverse event
a ‘‘Dominant’’ indicates greater health beneﬁts (survival, clinical response) and lower cost
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In all PSA simulations of the total cost per
patient, the incremental cost per patient
(comparing isavuconazole vs. voriconazole)
was less than $50,000 (ESM Appendix 3). In
80.2% of those simulations, isavuconazole was
associated with a lower total cost per patient
than voriconazole. At a willingness to pay
(WTP) of $50,000 per death avoided, 82.4% of
simulations found isavuconazole to be
cost-effective compared to voriconazole on the
basis of NMB values (ESM Appendix 3). Similar
results were seen when the cost per clinical
Table 3 Deterministic sensitivity analysis results, ISAV vs. VORI
















Changing the inputs for both ISAV and VORI
Treatment duration (IV) -$7173.91 -$7661.64 Dominant Dominant Dominant Dominant
Treatment duration (oral) -$7703.00 -$7132.55 Dominant Dominant Dominant Dominant
Total treatment duration -$7522.57 -$7312.98 Dominant Dominant Dominant Dominant
Initial hospital length of stay
(±25.0%)
-$6161.21 -$8674.34 Dominant Dominant Dominant Dominant
Initial hospital length of stay (mean
values)
-$2200.00 Dominant Dominant
Readmission length of stay -$7151.85 -$7683.70 Dominant Dominant Dominant Dominant
Readmission rate -$7327.91 -$7484.42 Dominant Dominant Dominant Dominant
Per diem cost of hospitalization -$5702.70 -$9132.86 Dominant Dominant Dominant Dominant
Total cost of AEs -$7352.95 -$7482.61 Dominant Dominant Dominant Dominant
Drug prices (IV and oral) -$7343.24 -$7492.31 Dominant Dominant Dominant Dominant
Payer perspective -$4833.26 Dominant Dominant
Equal initial length of stay,
mortality rate, and clinical response
rate
-$1411.05 – –
Mortality rate – – Dominant Dominant Dominant Dominant
Clinical response rate – – Dominant Dominant Dominant Dominant
Changing the inputs for ISAV only
Initial hospital length of stay -$17,295.94 $2460.39 Dominant $158,459.35 Dominant $143,398.88
Readmission rate -$8216.44 -$6477.45 Dominant Dominant Dominant Dominant
Mortality rate – – Dominant $198,126.42 – –
Clinical response rate – – – – $106,054.92 Dominant
ISAV isavuconazole, VORI voriconazole, IV intravenous, AE adverse event
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responder was considered. At a WTP of $50,000
per clinical responder, 81.8% of simulations
indicated isavuconazole to be cost-effective
compared to voriconazole on the basis of NMB
values (ESM Appendix 3).
DISCUSSION
The current standard of care for the treatment
of IA is voriconazole. However, isavuconazole, a
novel triazole, was recently introduced in the
USA for the treatment of IA. An appealing
alternative treatment option, isavuconazole
has comparable efficacy as voriconazole and
isavuconazole is well tolerated compared with
voriconazole, with fewer drug-related adverse
events. Findings from this economic evaluation
show that isavuconazole is associated with
lower costs per treated patient and is a
cost-effective option compared to voriconazole
for the treatment of IA. Isavuconazole
dominates voriconazole in terms of
incremental cost per additional death avoided
and per additional clinical responder.
In our analyses, the difference in the cost of
hospitalization was the main driver of the
difference in total costs between isavuconazole
and voriconazole, contributing to 92.0% of the
difference in total cost. Isavuconazole-treated
patients were associated with a shorter duration
of initial stay and lower rate of readmission
compared to voriconazole-treated patients,
leading to a lower hospitalization cost.
Isavuconazole’s shorter duration of treatment
and fewer doses per day from day 3 onward led
to lower isavuconazole drug cost, compared to
voriconazole, despite a higher drug cost per day.
Isavuconazole’s lower incidence rates of AEs
also translated into additional cost saving. As a
result, the use of isavuconazole may lead to a
cost saving of $7417.78 per patient compared to
voriconazole.
The study results were robust. In most
sensitivity analyses, isavuconazole was
associated with lower cost and greater health
benefits (dominating scenario) compared to
voriconazole. Only in situations where the
initial length of hospital stay, mortality rate,
and clinical response rate were made wholly
unfavorable for isavuconazole (while
maintaining voriconazole inputs) was
isavuconazole no longer associated with cost
savings or dominance, compared to
voriconazole. Given the fact that
isavuconazole is associated with numerically
shorter length of stay, lower mortality, and
higher response rates compared to voriconazole
in the SECURE trial, these worst-case scenarios
seem highly unlikely [17]. Even when LOS,
mortality rate, and clinical response rate were
assumed to be equal, isavuconazole was still
associated with a lower cost per patient owing
to the lower rate of readmission and associated
readmission costs. In about 80.0% of the PSA
simulations, isavuconazole is less costly than
voriconazole; in the majority of the simulations
(approx. 82% of cases), isavuconazole is also
more cost-effective than voriconazole at a WTP
of $50,000 per additional outcome.
No prior studies have compared the
cost-effectiveness of isavuconazole vs.
voriconazole in the treatment of IA; however,
there are multiple studies comparing
voriconazole to other IA treatments [13, 38].
Those studies have concluded that voriconazole
is the preferred therapy for IA in terms of
cost-effectiveness. The current study utilized a
similar methodology as these prior studies and
found that isavuconazole is associated with a
lower cost per patient and dominates
voriconazole in cost-effectiveness analysis for
the treatment of IA in the hospital setting.
The results of this study demonstrate that
isavuconazole is a valuable addition to the IA
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armamentarium. The efficacy of isavuconazole
is similar to that of voriconazole. Isavuconazole,
however, is associated with a lower total cost
per patient and is cost-effective compared to
voriconazole. In the USA, where the cost of
healthcare is steadily increasing,
cost-effectiveness analyses are increasingly
important in helping healthcare
decision-makers to evaluate different
reimbursement decisions and in helping
physicians and patients make the optimal
selection of therapy for a given condition.
Given that IA imposes a substantial economic
and clinical burden on society [8, 9], optimizing
the treatment of IA by evaluating the
cost-effectiveness of alternative treatment
options could help improve the care and
reduce the overall healthcare spending.
Evidence from the current study could support
payers and physicians in the process of therapy
selection for the treatment of IA by providing
valuable information for effective
decision-making.
Limitations
This economic evaluation is subject to several
limitations. First, the model did not consider
costs of treating any underlying conditions. The
costs associated with treating underlying
diseases can be substantial and may vary
greatly by disease condition. There is,
however, no evidence that treatment with
isavuconazole or voriconazole could impact
the costs of underlying disease conditions.
Second, in order to make an informed
comparison of first-line treatment with
isavuconazole vs. voriconazole, no subsequent
therapy was considered. The results of the
SECURE trial indicated that the clinical
response rate was numerically higher (not
statistically significant) with isavuconazole
than with voriconazole treatment; therefore,
not including subsequent treatment is expected
to be conservative against the isavuconazole
arm, where a lower proportion of patients
might receive subsequent therapy and incur
associated costs. Additionally, although clinical
trials are the gold standard for determining the
comparative efficacy of alternative treatments,
they often have restrictive inclusion and
exclusion criteria and thus patients in the trial
may lack the heterogeneity presented in
real-world clinical practice. Finally, as the
perspective of this study was that of a US
hospital (and US payer, in sensitivity analysis),
our results may not be generalizable to other
countries with different healthcare systems,
practices, and prices.
CONCLUSIONS
This economic evaluation shows that
isavuconazole may be a cost-effective option
compared to voriconazole for the treatment of
IA in the hospital setting. Isavuconazole was
associated with a lower total cost per patient
and dominated voriconazole in terms of
incremental costs per additional death avoided
and cost per additional clinical responder.
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